Drug Type Multi-specific antibody |
Synonyms- |
Action antagonists |
Mechanism CXCR1 antagonists(C-X-C motif chemokine receptor 1 antagonists), CXCR2 antagonists(C-X-C motif chemokine receptor 2 antagonists), CXCR3 antagonists(C-X-C motif chemokine receptor 3 antagonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | Japan | 03 Feb 2024 |